ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
Seaport Therapeutics
A Director, Biostatistics at Seaport Therapeutics leads statistical scientific strategy for clinical development programs spanning Phase 1–3, providing expert guidance on trial design, analysis, and regulatory interactions while mentoring junior team members.
Seaport Therapeutics is a biotechnology company developing novel neuropsychiatric medicines. The company applies its Glyph platform to advance potentially best-in-class therapeutics designed to improve efficacy and tolerability for patients with depression, anxiety, and other neuropsychiatric disorders.
Business WireSeaport Therapeutics and Monash Institute of Pharmaceutical Sciences Awarded up to $15 Million from ARPA‑H to Advance Seaport’s GlyphCele™, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function
2 weeks ago
Yahoo FinanceSeaport Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Jan 5, 2026
BioSpaceSeaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials
3 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Seaport Therapeutics.
5% above the average for this role
